Alpha-ketoglutarate supplementation reduces inflammation and thrombosis in type 2 diabetes by suppressing leukocyte and platelet activation
Clinical and Experimental Immunology · 2023
DOI: 10.1093/cei/uxad086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2023. Verfasst von Sakshi Agarwal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Regional Centre for Biotechnology, National Capital Region Biotech Science Cluster, Faridabad, India. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Thrombosis, Cardiovascular Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Science and Engineering Research Board.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The interplay between platelets and leukocytes contributes to the pathogenesis of inflammation, thrombosis, and cardiovascular diseases (CVDs) in type 2 diabetes (T2D). Our recent studies described alpha-ketoglutarate (αKG), a Krebs cycle intermediate metabolite as an inhibitor to platelets and leukocytes activation by suppressing phosphorylated-Akt (pAkt) through augmentation of prolyl hydroxylase-2 (PHD2). Dietary supplementation with a pharmacological concentration of αKG significantly inhibited lung inflammation in mice with either SARS-CoV-2 infection or exposed to hypoxia treatment. We therefore investigated if αKG supplementation could suppress hyperactivation of these blood cells and reduce thromboinflammatory complications in T2D. Our study describes that dietary supplementation with αKG (8 mg/100 g body wt. daily) for 7 days significantly reduced the activation of platelets and leukocytes (neutrophils and monocytes), and accumulation of IL1β, TNFα, and IL6 in peripheral blood of T2D mice. αKG also reduced the infiltration of platelets and leukocytes, and accumulation of inflammatory cytokines in lungs by suppressing pAkt and pP65 signaling. In a cross-sectional investigation, our study also described the elevated platelet–leukocyte aggregates and pro-inflammatory cytokines in circulation of T2D patients. T2D platelets and leukocytes showed an increased aggregation and thrombus formation in vitro. Interestingly, a pre-incubation of T2D blood samples with octyl αKG significantly suppressed the activation of these blood cells and ameliorated aggregate/thrombus formation in vitro. Thus, suggesting a potential therapeutic role of αKG against inflammation, thrombosis, and CVDs in T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regional Centre for Biotechnology, National Capital Region Biotech Science Cluster, Faridabad, India.
- Endocrinology & Metabolism, All India Institute of Medical Sciences, New Delhi, India.
ORCID-Profile: Prasenjit Guchhait
Förderung
- Science and Engineering Research Board
Zitieren
APA
Agarwal, S., Ghosh, R., Verma, G., Khadgawat, R., & Guchhait, P. (2023). Alpha-ketoglutarate supplementation reduces inflammation and thrombosis in type 2 diabetes by suppressing leukocyte and platelet activation. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxad086
Vancouver
Agarwal S, Ghosh R, Verma G, Khadgawat R, Guchhait P. Alpha-ketoglutarate supplementation reduces inflammation and thrombosis in type 2 diabetes by suppressing leukocyte and platelet activation. Clinical and Experimental Immunology. 2023. doi:10.1093/cei/uxad086
BibTeX
@article{Agarwal2023,
author = {Agarwal, Sakshi and Ghosh, Riya and Verma, Garima and Khadgawat, Rajesh and Guchhait, Prasenjit},
title = {Alpha-ketoglutarate supplementation reduces inflammation and thrombosis in type 2 diabetes by suppressing leukocyte and platelet activation},
journal = {Clinical and Experimental Immunology},
year = {2023},
doi = {10.1093/cei/uxad086}
}
EUVIMED